Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

The potential of the superoxide dismutase inhibitor, diethyldithiocarbamate as an adjuvant to radiotherapy

It has long been known that oxygen has the potential to be toxic to biologic systems and that this toxicity is not due to oxygen itself, but due to the production of oxygen radicals. One of these potentially toxic radicals, superoxide (O₂⁻) can be generated as a result of ionizing radiation, and if...

Full description

Saved in:
Bibliographic Details
Main Author: Kent, Charles
Other Authors: Blekkenhorst, Gerhardus Hendrikus
Format: Thesis
Language:English
Published: Division of Radiology 2017
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867613144479694848
access_status_str Open Access
author Kent, Charles
author2 Blekkenhorst, Gerhardus Hendrikus
author_browse Blekkenhorst, Gerhardus Hendrikus
Kent, Charles
author_facet Blekkenhorst, Gerhardus Hendrikus
Kent, Charles
author_sort Kent, Charles
collection Thesis
description It has long been known that oxygen has the potential to be toxic to biologic systems and that this toxicity is not due to oxygen itself, but due to the production of oxygen radicals. One of these potentially toxic radicals, superoxide (O₂⁻) can be generated as a result of ionizing radiation, and if not adequately removed can proceed to cause cell damage. Superoxide dismutase (SOD) is one of the key enzymes involved in the defence against oxygen toxicity. SOD activity can be inhibited by diethyldithiocarbamate (DOC), a powerful copper chelator. If inhibition of SOD by DOC increases the lifetime and effectiveness of radiation induced O₂⁻, it follows that the potential exists for DOC to enhance the effect of radiation. DOC is however also a thiol compound, and thus may act as a radioprotector by modifying tissue oxygenation status or by free radical scavenging. This study has concerned itself primarily with the inhibition of superoxide dismutase by diethyldithiocarbamate in order to sensitize tumours to ionizing radiation. The use of DOC as an inhibitor of SOD has however meant that any sensitization resulting from SOD inhibition could be masked by a radioprotective effect by DOC. The inhibition of SOD by DDC was confirmed in a murine rhabdomyosarcoma, and it was shown that this inhibition can be maintained for up to twenty-four hours after DDC administration. It was hypothesised that there was a potential for the radioprotective effect of DDC to be overcome, if the levels of DDC were low enough at the time of irradiation. Indeed, if DDC was removed from the growth medium of B16 mouse melanoma cells in culture prior to irradiation, a significant sensitization was demonstrated. It was shown that DDC could act as both a radiosensitizer and as a radioprotector in the same experiment. The dominant action of DDC was found to be dependent on the time allowed between DDC administration and irradiation. If this time was approximately 4 hours, it was possible to show a radiosensitizing effect by means of a tumour growth delay assay. This time modulation effect of DOC was shown in larger tumours, rather than smaller tumours, which could indicate that tumour oxygenation is an important criterion in determining the response to radiation of DOC treated cells. It was shown that B16 mouse melanoma cells exposed to 43°C after DDC pre-treatment were sensitized to thermal damage. This work suggests that some caution should be exercised when DDC is put forward as either a radiosensitizer or a radioprotector in the clinic, but that DDC may have potential as a thermosensitizer.
format Thesis
id oai:open.uct.ac.za:11427/26550
institution University of Cape Town (South Africa)
language eng
last_indexed 2026-06-10T12:31:28.055Z
license_str Not specified — see source repository
provenance_str_mv Harvested via OAI-PMH from UCTD — University of Cape Town Open Access Repository
publishDate 2017
publishDateRange 2017
publishDateSort 2017
publisher Division of Radiology
publisherStr Division of Radiology
record_format dspace
source_str UCTD — University of Cape Town Open Access Repository
spelling oai:open.uct.ac.za:11427/26550 The potential of the superoxide dismutase inhibitor, diethyldithiocarbamate as an adjuvant to radiotherapy Kent, Charles Blekkenhorst, Gerhardus Hendrikus Ditiocarb Radiobiology Radiotherapy Superoxide Dismutase - antagonists & inhibitors It has long been known that oxygen has the potential to be toxic to biologic systems and that this toxicity is not due to oxygen itself, but due to the production of oxygen radicals. One of these potentially toxic radicals, superoxide (O₂⁻) can be generated as a result of ionizing radiation, and if not adequately removed can proceed to cause cell damage. Superoxide dismutase (SOD) is one of the key enzymes involved in the defence against oxygen toxicity. SOD activity can be inhibited by diethyldithiocarbamate (DOC), a powerful copper chelator. If inhibition of SOD by DOC increases the lifetime and effectiveness of radiation induced O₂⁻, it follows that the potential exists for DOC to enhance the effect of radiation. DOC is however also a thiol compound, and thus may act as a radioprotector by modifying tissue oxygenation status or by free radical scavenging. This study has concerned itself primarily with the inhibition of superoxide dismutase by diethyldithiocarbamate in order to sensitize tumours to ionizing radiation. The use of DOC as an inhibitor of SOD has however meant that any sensitization resulting from SOD inhibition could be masked by a radioprotective effect by DOC. The inhibition of SOD by DDC was confirmed in a murine rhabdomyosarcoma, and it was shown that this inhibition can be maintained for up to twenty-four hours after DDC administration. It was hypothesised that there was a potential for the radioprotective effect of DDC to be overcome, if the levels of DDC were low enough at the time of irradiation. Indeed, if DDC was removed from the growth medium of B16 mouse melanoma cells in culture prior to irradiation, a significant sensitization was demonstrated. It was shown that DDC could act as both a radiosensitizer and as a radioprotector in the same experiment. The dominant action of DDC was found to be dependent on the time allowed between DDC administration and irradiation. If this time was approximately 4 hours, it was possible to show a radiosensitizing effect by means of a tumour growth delay assay. This time modulation effect of DOC was shown in larger tumours, rather than smaller tumours, which could indicate that tumour oxygenation is an important criterion in determining the response to radiation of DOC treated cells. It was shown that B16 mouse melanoma cells exposed to 43°C after DDC pre-treatment were sensitized to thermal damage. This work suggests that some caution should be exercised when DDC is put forward as either a radiosensitizer or a radioprotector in the clinic, but that DDC may have potential as a thermosensitizer. 2017-12-11T14:15:56Z 2017-12-11T14:15:56Z 1990 Doctoral Thesis Doctoral PhD http://hdl.handle.net/11427/26550 eng application/pdf Division of Radiology Faculty of Health Sciences University of Cape Town
spellingShingle Ditiocarb
Radiobiology
Radiotherapy
Superoxide Dismutase - antagonists & inhibitors
Kent, Charles
The potential of the superoxide dismutase inhibitor, diethyldithiocarbamate as an adjuvant to radiotherapy
thesis_degree_str Doctoral
title The potential of the superoxide dismutase inhibitor, diethyldithiocarbamate as an adjuvant to radiotherapy
title_full The potential of the superoxide dismutase inhibitor, diethyldithiocarbamate as an adjuvant to radiotherapy
title_fullStr The potential of the superoxide dismutase inhibitor, diethyldithiocarbamate as an adjuvant to radiotherapy
title_full_unstemmed The potential of the superoxide dismutase inhibitor, diethyldithiocarbamate as an adjuvant to radiotherapy
title_short The potential of the superoxide dismutase inhibitor, diethyldithiocarbamate as an adjuvant to radiotherapy
title_sort potential of the superoxide dismutase inhibitor diethyldithiocarbamate as an adjuvant to radiotherapy
topic Ditiocarb
Radiobiology
Radiotherapy
Superoxide Dismutase - antagonists & inhibitors
url http://hdl.handle.net/11427/26550
work_keys_str_mv AT kentcharles thepotentialofthesuperoxidedismutaseinhibitordiethyldithiocarbamateasanadjuvanttoradiotherapy
AT kentcharles potentialofthesuperoxidedismutaseinhibitordiethyldithiocarbamateasanadjuvanttoradiotherapy